Advancing Cancer Treatment
The Therapeutics Discovery division at MD Anderson was created to eliminate the bottlenecks that hamper traditional drug development.
Our team of more than 100 dedicated cancer researchers, doctors, drug developers and scientific experts develops small molecule drugs, biologics and cellular therapies, inspired by the needs of MD Anderson cancer patients and guided by the expertise of the center’s clinicians. To create life-saving transformational medicines quickly, safely and effectively, Therapeutics Discovery works with unparalleled proximity to patients and an unmatched wealth of clinical experience.
Therapeutics Discovery doesn’t bring the “bench to bedside” – it starts with the bench at the bedside – with each patient and their cancer.
The platforms of Therapeutics Discovery are supported by MD Anderson’s Moon Shots Program®.
We have leveraged our unique approach to discover and advance novel small-molecule, biologic and cell-based therapies to answer unmet needs that will improve the lives of our patients.Learn more about our therapeutics pipeline
In the News
Stay up to date on our new collaborations and recent progress.
Discovering and developing new treatments for cancer is a difficult process with many obstacles. These challenges can slow the process of bringing new therapies to patients. That’s why MD Anderson built the Therapeutics Discovery division, to overcome these hurdles.
This unique team of physicians, researchers, and drug discovery and development experts collaborates across the institution to advance new therapies, providing unique insights that can help with drug development.
MD Anderson’s extensive clinical and laboratory research infrastructure enables the team to efficiently advance new medicines from the discovery phase all the way into clinical trials. They have successfully developed a number of new therapies, including recent progress on treatments for certain patients with leukemia, lung cancer, liver cancer, and head and neck cancers.
New targeted therapy enters clinical trial for advanced lung cancer and other solid tumors
A new drug targeting a protein called SHP2 has entered a Phase I clinical trial for patients with advanced lung cancers and other solid tumor types driven by gene mutations that activate the MAPK signaling pathway -- notably KRAS, EGFR and others.
The drug, known as BBP-398, is being developed in collaboration with Navire Pharma, an affiliate of BridgeBio Pharma, Inc. It was initially discovered and developed by scientists in the Institute for Applied Cancer Science (IACS) and Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) platforms, both part of the Therapeutics Discovery division.
Many therapies used to treat solid tumors target components of the MAPK signaling pathway, but cancers often become resistant to these drugs. A preclinical study led by Therapeutics Discovery and Navire scientists found that SHP2 inhibitors were effective in blocking the MAPK pathway and overcoming resistance to available therapies.
“Because SHP2 works downstream in these pathways, targeting this protein makes an attractive treatment strategy for patients with lung cancer who are no longer responding to treatments like osimertinib,” says Yuting Sun, Ph.D., co-project lead and senior research scientist with TRACTION. “We are eager to see how this new drug performs in clinical trials and to continue advancing it for patients in need of better treatment options.”
The Phase I study is designed to determine the correct treatment dose for future trials and evaluate the safety and activity of this therapy in patients with advanced cancers with mutations in MAPK signaling. David Hong, M.D., is leading the clinical trial.
First-in-class therapy for patients with liver, head and neck cancers
Working in collaboration with Ionis Pharmaceuticals, the Therapeutics Discovery team is using a different approach to target previously undruggable biological pathways in difficult to treat liver cancers. This approach relies on an antisense oligonucleotide (ASO), which is a small piece of synthetic genetic material rather than a classical chemical drug compound. The ASO are able to block the activity of target genes inside a cancer cell and stop the proteins from being made.
Working closely with Ionis and other MD Anderson researchers, members of the TRACTION platform have helped to advance an ASO that targets YAP1, which regulates cell growth and survival. YAP1 is overactive in several cancer types, including liver cancer and certain head and neck cancers with a specific genetic mutation.
Laboratory experiments show that the ASO targeting YAP1 is effective in treating these cancers in animal models. Based on those promising preclinical studies, the therapy has now entered a Phase I clinical trial at MD Anderson, led by Timothy Yap, M.B.B.S., Ph.D.
“This antisense oligonucleotide represents a novel, first-in-class therapeutic option, and we hope that it will prove to be a promising new treatment for patients with tumors driven by high YAP1 activity,” says Tim Heffernan, Ph.D., executive director of TRACTION.
Creating new targeted therapies for patients with genetically defined leukemias and lymphomas
While our genes are passed onto us by our parents, the epigenome is a set of instructions for the cell laid on top of our genes. These chemical modifications help control gene expression, like a light switch and dimmer. Disruptions to the epigenome are a hallmark of cancer development, so targeting epigenetic functions are an attractive target for cancer therapies.
Therapeutics Discovery scientists are actively working to develop a new targeted therapy against an epigenetic regulator protein called CBP/p300. This protein is responsible for cancer development in certain patients with early onset acute myeloid leukemia and diffuse large B cell lymphoma.
“We recognize these patients do not currently have effective treatment options available to them. We are actively working to advance a CBP/p300 inhibitor that we hope will lead to an impactful new medicine,” says Phil Jones, Ph.D., vice president of Therapeutics Discovery.
The work to develop this new therapy is supported by The Mark Foundation for Cancer Research, who recently launched a Drug Discovery Partnership with IACS. This new targeted therapy is expected to enter clinical trials in 2021 and could represent the first CBP/p300 inhibitor to be clinically tested in these patients.
Request an appointment at MD Anderson online or by calling 1-877-632-6789.
The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.
This collaboration joins Xencor’s innovative XmAb® technology and protein engineering expertise to create bispecific antibodies with MD Anderson’s expertise in the research and discovery of novel therapeutic antibodies, including the Oncology Research for Biologics and Immunotherapy Translation (ORBIT) platform, part of MD Anderson’s Therapeutics Discovery division.
“Xencor’s modular antibody engineering platform enables the rapid generation of XmAb® bispecific antibodies, and our research collaboration with MD Anderson will further expand the use of our technology to explore novel therapeutic targets, which could result in the creation of new therapies for patients with cancer,” said John Desjarlais, Ph.D., senior vice president and chief scientific officer at Xencor.
T cell-engaging bispecific antibodies are designed to recognize and bind to an antigen on tumor cells as well as an activating receptor on T cells, such as CD3, in order to directly recruit and activate T cells against tumor cells. Xencor’s modular scaffold for engineering bispecific antibodies is the XmAb bispecific Fc domain, which enables the rapid creation of stable antibodies with novel anti-tumor mechanisms of action.
"There is an urgent need to discover new therapeutic targets and to develop antibody-based strategies to trigger an immune response against the tumors that express them," said Dongxing Zha, Ph.D., institute head of the ORBIT platform at MD Anderson. "Xencor's multi-format-capable CD3 bispecific antibody platform enables us to rapidly develop and investigate therapies against intriguing tumor targets, and we look forward to evaluating the first candidates to be engineered as part of this collaboration."
MD Anderson will work to identify and develop potential antibodies, collaborating with Xencor to apply its XmAb bispecific technology to create therapeutic candidates. MD Anderson will then conduct and fund all preclinical activities to advance candidates toward clinical studies.
Xencor has certain exclusive options to license worldwide rights to develop and commercialize potential new medicines arising from the research collaboration. For programs not licensed by Xencor, Xencor will receive a portion of future payments received by MD Anderson. Xencor and MD Anderson are entering into the collaboration with two predetermined, undisclosed antibody candidates.
Our Unique Model
We are a drug development engine built within MD Anderson, taking an approach unlike anywhere else. Our experienced teams work collaboratively across industry-scale research platforms to advance new therapies, and we collaborate with leading biopharmaceutical companies to bring new medicines to patients in need.Learn more about our approach